Cancer News and Research

Latest Cancer News and Research

Merit Medical Systems to acquire BioSphere Medical

Merit Medical Systems, Inc. today announced that it has signed a definitive merger agreement to acquire BioSphere Medical, Inc. in an all cash transaction valued at approximately $96 million, inclusive of all common equity and Series A Preferred preferences.

14 May 2010

Groups plead for more health funding as Chairman warns about cuts to proposed HHS budget

House Appropriations Committee Chairman David Obey, D-Wis., said Wednesday that groups pressing for $14 billion more in funding for education, health and labor programs will likely be disappointed because the budget proposed by President Barack Obama already faces cuts of about $3.5 billion in those areas.

14 May 2010

Cyclacel Pharmaceuticals reports net loss of $5.1M for first-quarter 2010

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the first quarter ended March 31, 2010.

14 May 2010

Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will initiate a Phase IIb clinical trial for ZoraxelTM in the treatment of erectile dysfunction (ED).

13 May 2010

TechniScan awarded U.S. Patent for 3-D, Warm Bath Ultrasound system

A newly awarded U.S. Patent will protect TechniScan, Inc's., novel way to image, biopsy and treat breast cancer.

13 May 2010

Genta first-quarter net loss increases to $166.6 million

Genta Incorporated today announced financial results for the quarter ended March 31, 2010.

13 May 2010

Arrowhead decreases second-quarter consolidated operating expenses by 58%

Arrowhead Research Corporation today announced financial results for its fiscal 2010 second quarter ended March 31, 2010.

13 May 2010

Researchers provide better understanding of anti-cell death proteins and potential antagonist to defeat them

Cancer uses devious means to evade treatment and survive. One prime example is the way tumors express anti-cell death (anti-apoptotic) proteins to resist chemotherapy and radiation. However, the Pellecchia laboratory at Sanford-Burnham Medical Research Institute has made two recent discoveries that may help curb these anti-apoptotic proteins and make current treatments more effective.

13 May 2010

CyGene Laboratories reports heightened interest in at-home genetic testing

CyGene Laboratories Inc. today announced that it has experienced unprecedented levels of interest and requests for information following recent media coverage of Walgreens' decision to offer genetics testing kits supplied by Pathway Genomics in certain of their retail stores.

13 May 2010

Genetic Immunity formulates first topically administered nanomedicine therapeutic vaccine for HIV/AIDS

Genetic Immunity, a multi-national biopharmaceutical company developing nanomedicine vaccines today announces publication of the Company's innovative work to develop a stable liquid formulation to deliver a novel nanomedicine. Appearing in the International Journal of Pharmaceutics, the paper addresses how Genetic Immunity was able to overcome significant hurdles facing the field to successfully formulate the first topically administered nanomedicine therapeutic vaccine for the treatment of HIV/AIDS, DermaVir.

13 May 2010

Daily consumption of probiotic cheese helps tackle age-related changes in immune system: Research

Scientists in Finland have discovered that cheese can help preserve and enhance the immune system of the elderly by acting as a carrier for probiotic bacteria. The research, published in FEMS Immunology & Medical Microbiology, reveals that daily consumption of probiotic cheese helps to tackle age-related changes in the immune system.

13 May 2010

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results as at and for the three months ended March 31, 2010.

13 May 2010

Research article focuses on how IECs respond to probiotic strain B. lactis HN019

Probiotics are a group of live microorganisms administered in adequate amounts which confer a beneficial health effect on the host. This bacterial community plays a pivotal role in human nutrition and health by promoting the supply of nutrients, preventing pathogen colonization and shaping and maintaining normal mucosal immunity.

13 May 2010

SAGE launches further two Therapeutic Advances journals

SAGE has extended its suite of Therapeutic Advances journals with the launch of a further two titles: Therapeutic Advances in Chronic Disease and Therapeutic Advances in Endocrinology and Metabolism.

13 May 2010

Increased IR associated with HCC development in chronic HCV-infected patients

Recent studies have demonstrated that type 2 diabetes mellitus (DM) is associated with high risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C. Insulin resistance (IR), which correlates inversely with circulating adiponectin concentration, is a consistent finding in patients with type 2 DM.

13 May 2010

Trubion Pharmaceuticals to present promising data from Phase 1 studies of SBI-087, SBI-087

Trubion Pharmaceuticals, Inc. today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both abstracts are available at http://www.eular.org. SBI-087 is Trubion's next-generation CD20-directed small modular immunopharmaceutical (SMIP™) product candidate and is being developed in collaboration with Pfizer.

13 May 2010

Cancer Research UK to unveil its eighth garden at Chelsea Flower Show 2010

Cancer Research UK will unveil its eighth garden at Chelsea Flower Show 2010 (25 - 29 May 2010), designed for the second year running by four-time gold medal winner, Robert Myers.

13 May 2010

Research investigates MDR in human HCC

Hepatocellular carcinoma responds poorly to chemotherapy owing to MDR. Recent studies have shown the tumors derived from the colon, kidney, or adrenal cortex, and HCC exhibited overexpression of MDR1/P-gp. This overexpression results in a primary MDR phenotype of these cancers.

13 May 2010

Researchers to discuss various implications for personalized medicine during one-day symposium

On May 27, researchers with the National Human Genome Research Institute and the National Cancer Institute, along with Group Health Cooperative in Seattle and Henry Ford Health System, will debate and discuss that question during the one-day symposium "Multiplex Initiative: Implications for Personalized Medicine."

13 May 2010

27-year-old sickle cell disease patient undergoes multiple joint replacement surgery

Fortis Hospitals Mulund, Mumbai, performed a multiple joint replacement surgery on a 27 year old young Nigerian patient. Rebacca underwent a hip and a shoulder replacement surgery by Dr. Sachin Bhonsle, Consultant Orthopedic Surgeon, after years of suffering in pain and immobility.

13 May 2010

Cancer News and Research

Latest Cancer News and Research

Merit Medical Systems to acquire BioSphere Medical

Groups plead for more health funding as Chairman warns about cuts to proposed HHS budget

Cyclacel Pharmaceuticals reports net loss of $5.1M for first-quarter 2010

Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED

TechniScan awarded U.S. Patent for 3-D, Warm Bath Ultrasound system

Genta first-quarter net loss increases to $166.6 million

Arrowhead decreases second-quarter consolidated operating expenses by 58%

Researchers provide better understanding of anti-cell death proteins and potential antagonist to defeat them

CyGene Laboratories reports heightened interest in at-home genetic testing

Genetic Immunity formulates first topically administered nanomedicine therapeutic vaccine for HIV/AIDS

Daily consumption of probiotic cheese helps tackle age-related changes in immune system: Research

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Research article focuses on how IECs respond to probiotic strain B. lactis HN019

SAGE launches further two Therapeutic Advances journals

Increased IR associated with HCC development in chronic HCV-infected patients

Trubion Pharmaceuticals to present promising data from Phase 1 studies of SBI-087, SBI-087

Cancer Research UK to unveil its eighth garden at Chelsea Flower Show 2010

Research investigates MDR in human HCC

Researchers to discuss various implications for personalized medicine during one-day symposium

27-year-old sickle cell disease patient undergoes multiple joint replacement surgery

Understanding the DNA Damage Response in Innate Immunity eBook

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

The importance of ketones from a clinical and medical perspective

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

The importance of ketones from a clinical and medical perspective

Newsletters you may be interested in